Therapeutics

#Digital therapeutics #GlobalData #Pharmaceuticals #Therapeutics

Opportunities in Japan’s neurology digital therapeutics market

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions; GlobalData says several opportunities exist in the digital therapeutics market for neurological diseases in Japan.  Shionogi & Co, a partner of Akili Interactive, a prescription digital medicine company of PureTech Health, has… Read More

#News #Trends & Analysis

#Drug discovery #iPSC #Stem cells #Therapeutics

Therapeutics research partnership to access induced Pluripotent Stem Cells 

Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise.  Bone Therapeutics has developed a bone marrow-derived off-the-shelf, allogeneic MSC cell therapy platform. Read More

#News

#Biology #Cancer research #Immuno-oncology #Systems biology #Therapeutics #Webinar

Targeted protein degradation: learn from an expert 

Challenges and Opportunities in Protein Degradation, is free webinar hosted by DDW and supported by Cell Signaling Technology (CST). It took place on 21 October, 2021 and is now available to watch on demand for free here.   Dr. Nathanael Gray, Professor of… Read More

#News

#Antibodies #Covid-19 #Drug development #Drug discovery #Preclinical development #Therapeutics

Highlights of Carterra’s Bamlanivimab story

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application… Read More

#Covid-19 #Exclusive Content #News

#Cancer research #Cell therapy #Therapeutics

First-in-human Phase I trial begun for AML treatment 

GammaDelta Therapeutics has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy manufactured from healthy donor blood.  AML is the most common form of acute leukaemia in adults with an… Read More

#News

#Cancer immunotherapy #Cancer research #Drug discovery #Immuno-oncology #Systems biology #Therapeutics #Webinar

Event examines emerging strategy for cancer therapeutic development 

In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD).  Challenges and Opportunities in Protein Degradation, took place on… Read More

#News

#Biopharmaceuticals #Clinical research #Drug development #Therapeutics

Antibody-mediated therapies: meeting the challenges in R&D

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by… Read More

#Editor's Choice #Exclusive Content #News

Human brain
#Biomarkers #Clinical research #Schizophrenia #Therapeutics

Study to overcome biological heterogeneity challenges by 2022 

Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia.  Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

#Biotechnology #Clinical trials #CRISPR #Market reporting #Therapeutics

Report predicts trends and forecasts for CRISPR 

The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.  The report features a study of the current market landscape and future opportunity for the players involved in the development of CRISPR… Read More

#Business & Investment #Market Reports #News #Trends & Analysis

Covid-19
#Clinical trials #Covid-19 #Drug development #Oncology #Therapeutics

Oncology treatment tested in patients with moderate Covid-19 disease 

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More

#Covid-19 #News #Trending News

#Collaboration #Covid-19 #Therapeutics

Exscientia and Gates Foundation’s antiviral therapeutics  

Exscientia has entered a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics.   The collaboration will initially focus on developing broad-spectrum coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead programme,… Read More

#News

Seed funding
#Clinical trials #Covid-19 #Drug discovery #Funding #Research #Therapeutics

ILC Therapeutics completes £3.5 million funding round 

ILC Therapeutics has completed a £3.5 million pre-IPO funding round. Investors include Robert Kopple, Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management.  Chairman Peter Bains said: “With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte… Read More

#Business & Investment #News

#Pharmaceuticals #Schizophrenia #Therapeutics

New potential therapy for schizophrenia patients

Newron Pharmaceuticals has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Results from the study are expected by the fourth quarter of 2022.  Study 008A, a four-week, randomised, double-blind placebo-controlled international study, is designed to evaluate the efficacy, tolerability, and safety (including effects on the… Read More

#News

#Drug development #Oncology #Therapeutics

Avacta appoints Chief Scientific Officer of therapeutics division

Avacta has appointed Dr Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. Dr McLaughlin is an experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical… Read More

#Business & Investment #News

#Covid-19 #Drug development #Drug discovery #Podcast #Therapeutics

How Bamlanivimab reached clinic in eight months – podcast 

The latest DDW Sponsored Sitting Down With podcast features Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Co and Dan Bedinger, Application Science Team Lead, Carterra. Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild… Read More

#Covid-19 #News